Insulet

YTD

ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

CEO

Ashley A. McEvoy

CEOAshley A. McEvoy

Employees

5,400

Employees5,400

Headquarters

Acton, Massachusetts

HeadquartersActon, Massachusetts

Founded

2000

Founded2000

Employees

5,400

Employees5,400

PODD Key Statistics

Market cap

11.40B

Market cap11.40B

Price-Earnings ratio

38.28

Price-Earnings ratio38.28

Dividend yield

—

Dividend yield—

Average volume

1.83M

Average volume1.83M

High today

$167.82

High today$167.82

Low today

$159.31

Low today$159.31

Open price

$161.27

Open price$161.27

Volume

1.47M

Volume1.47M

52 Week high

$354.88

52 Week high$354.88

52 Week low

$138.79

52 Week low$138.79

Stock Snapshot

With a market cap of 11.4B, Insulet(PODD) trades at $164.48. The stock has a price-to-earnings ratio of 38.28.

On 2026-07-05, Insulet(PODD) stock moved within a range of $159.31 to $167.82. With shares now at $164.48, the stock is trading +3.2% above its intraday low and -2.0% below the session's peak.

Trading volume for Insulet(PODD) stock has reached 1.47M, versus its average volume of 1.83M.

The stock's 52-week range extends from a low of $138.79 to a high of $354.88.

PODD News

Investing.com 19h

Truist cuts Insulet stock price target to $250 on guidance concerns - Investing.com

...

TipRanks 2d

FDA says Insulet recalled certain Omnipod Pods

The FDA said it is aware that Insulet (PODD) issued a letter to affected customers recommending certain Omnipod Pods be removed from where they are used or sold...

TipRanks 3d

Insulet’s EVOLVE Trial Targets Big Type 2 Diabetes Opportunity With Omnipod M

Insulet (PODD) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more con...

Analyst ratings

86%

of 28 ratings

Buy

85.7%

Hold

14.3%

Sell

More PODD News

TipRanks 3d

Insulet’s Optimal-B Study: Real-World Omnipod 5 Data Investors Should Watch

Insulet (PODD) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more con...

Simply Wall St 4d

Insulet After Russell Index Inclusion With Fair Value Still In Focus

Insulet (PODD) has just been added to both the Russell 2500 and Russell 2500 Growth indexes, a change that can influence institutional ownership as index funds...

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.